Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)

BackgroundCell saver (CS) technology is an increasingly popular approach for autotransfusion in small animal veterinary medicine for the treatment of patients with abdominal hemorrhagic effusion.ObjectiveTo evaluate the utility, effectiveness, and safety of autotransfusions collected with a CS devic...

Full description

Saved in:
Bibliographic Details
Main Authors: Fabienne Blunschi, Dennis Gluding, Esther Hassdenteufel, Matthias Schneider, Hendrik Lehmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Veterinary Science
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2025.1465988/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832542296227184640
author Fabienne Blunschi
Dennis Gluding
Esther Hassdenteufel
Matthias Schneider
Hendrik Lehmann
author_facet Fabienne Blunschi
Dennis Gluding
Esther Hassdenteufel
Matthias Schneider
Hendrik Lehmann
author_sort Fabienne Blunschi
collection DOAJ
description BackgroundCell saver (CS) technology is an increasingly popular approach for autotransfusion in small animal veterinary medicine for the treatment of patients with abdominal hemorrhagic effusion.ObjectiveTo evaluate the utility, effectiveness, and safety of autotransfusions collected with a CS device and to assess whether the use of the CS device reduces the demand for allogenic blood transfusions.Materials and methodsRetrospective study of dogs with acute hemoperitoneum of splenic origin treated surgically. Dogs were grouped by the type of transfusion received: allo- and autotransfusion (AA), allotransfusion only (AO), autotransfusion only (CS), and no transfusion (NT). Differences in changes of laboratory parameters (hematocrit and lactate), transfusion volume, and outcomes were analyzed across groups.ResultsForty-three dogs were included. Twenty-seven (62.8%) suffered from hemangiosarcoma, and 16 (37.2%) had a benign cause of hemoperitoneum. The classification into blood transfusion groups was as follows: 7/43 (16.3%) in the AA-group, 11/43 (25.6%) in the AO-group, 11/43 (25.6%) in the CS-group and 14/43 (32.6%) in the NT-group. Increase in hematocrit over time was similar in all subgroups that received any form of blood transfusion (AA-, AO-, CS-group). Total volume of transfused blood (autologous and allogenic) was significantly higher in the AA-group (median 54.0mL/kg, range 24.7–126.5mL/kg) than in the AO-group (median 7.6mL/kg, range 4.6–13.5mL/kg, p = 0.01) but not the CS-group (median 23.8mL/kg, range 14.1–50.0mL/kg, p = 0.22). No difference was found for the volume of allogenic blood transfused between the AA-group (median 9.4mL/kg, range 5.0–16.2mL/kg) and AO-group (median 7.6mL/kg, range 4.6–13.5mL/kg) (p = 0.68). The use of the CS device did not adversely affect the time from presentation to surgery, the duration of surgery, or the outcomes.DiscussionThe use of autologous blood transfusions obtained by CS device in dogs suffering from acute hemoperitoneum caused by a benign or malignant splenic disorder appeared safe and effective in the cases described. And therefore may emphasize its further application as an addition or alternative to traditional allogenic blood transfusions.
format Article
id doaj-art-30dd5b24f60d4137be1a727cd6e63086
institution Kabale University
issn 2297-1769
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Veterinary Science
spelling doaj-art-30dd5b24f60d4137be1a727cd6e630862025-02-04T06:31:52ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692025-02-011210.3389/fvets.2025.14659881465988Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)Fabienne BlunschiDennis GludingEsther HassdenteufelMatthias SchneiderHendrik LehmannBackgroundCell saver (CS) technology is an increasingly popular approach for autotransfusion in small animal veterinary medicine for the treatment of patients with abdominal hemorrhagic effusion.ObjectiveTo evaluate the utility, effectiveness, and safety of autotransfusions collected with a CS device and to assess whether the use of the CS device reduces the demand for allogenic blood transfusions.Materials and methodsRetrospective study of dogs with acute hemoperitoneum of splenic origin treated surgically. Dogs were grouped by the type of transfusion received: allo- and autotransfusion (AA), allotransfusion only (AO), autotransfusion only (CS), and no transfusion (NT). Differences in changes of laboratory parameters (hematocrit and lactate), transfusion volume, and outcomes were analyzed across groups.ResultsForty-three dogs were included. Twenty-seven (62.8%) suffered from hemangiosarcoma, and 16 (37.2%) had a benign cause of hemoperitoneum. The classification into blood transfusion groups was as follows: 7/43 (16.3%) in the AA-group, 11/43 (25.6%) in the AO-group, 11/43 (25.6%) in the CS-group and 14/43 (32.6%) in the NT-group. Increase in hematocrit over time was similar in all subgroups that received any form of blood transfusion (AA-, AO-, CS-group). Total volume of transfused blood (autologous and allogenic) was significantly higher in the AA-group (median 54.0mL/kg, range 24.7–126.5mL/kg) than in the AO-group (median 7.6mL/kg, range 4.6–13.5mL/kg, p = 0.01) but not the CS-group (median 23.8mL/kg, range 14.1–50.0mL/kg, p = 0.22). No difference was found for the volume of allogenic blood transfused between the AA-group (median 9.4mL/kg, range 5.0–16.2mL/kg) and AO-group (median 7.6mL/kg, range 4.6–13.5mL/kg) (p = 0.68). The use of the CS device did not adversely affect the time from presentation to surgery, the duration of surgery, or the outcomes.DiscussionThe use of autologous blood transfusions obtained by CS device in dogs suffering from acute hemoperitoneum caused by a benign or malignant splenic disorder appeared safe and effective in the cases described. And therefore may emphasize its further application as an addition or alternative to traditional allogenic blood transfusions.https://www.frontiersin.org/articles/10.3389/fvets.2025.1465988/fullblood salvageautologous transfusionspleenhemangiosarcomablood transfusionhemoabdomen
spellingShingle Fabienne Blunschi
Dennis Gluding
Esther Hassdenteufel
Matthias Schneider
Hendrik Lehmann
Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
Frontiers in Veterinary Science
blood salvage
autologous transfusion
spleen
hemangiosarcoma
blood transfusion
hemoabdomen
title Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
title_full Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
title_fullStr Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
title_full_unstemmed Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
title_short Retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs (2017–2021)
title_sort retrospective evaluation of autotransfusion using a cell saver device versus allotransfusion in the perioperative management of acute hemoperitoneum in 43 dogs 2017 2021
topic blood salvage
autologous transfusion
spleen
hemangiosarcoma
blood transfusion
hemoabdomen
url https://www.frontiersin.org/articles/10.3389/fvets.2025.1465988/full
work_keys_str_mv AT fabienneblunschi retrospectiveevaluationofautotransfusionusingacellsaverdeviceversusallotransfusionintheperioperativemanagementofacutehemoperitoneumin43dogs20172021
AT dennisgluding retrospectiveevaluationofautotransfusionusingacellsaverdeviceversusallotransfusionintheperioperativemanagementofacutehemoperitoneumin43dogs20172021
AT estherhassdenteufel retrospectiveevaluationofautotransfusionusingacellsaverdeviceversusallotransfusionintheperioperativemanagementofacutehemoperitoneumin43dogs20172021
AT matthiasschneider retrospectiveevaluationofautotransfusionusingacellsaverdeviceversusallotransfusionintheperioperativemanagementofacutehemoperitoneumin43dogs20172021
AT hendriklehmann retrospectiveevaluationofautotransfusionusingacellsaverdeviceversusallotransfusionintheperioperativemanagementofacutehemoperitoneumin43dogs20172021